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Introduction
Squamous cell carcinoma (SCC) of the oral cavity typi-
cally occurs in men during the sixth and seventh
decades of life1. In Taiwan, there were 1,363 and 1,070
newly diagnosed patients with SCC over the subsites of
the oral tongue and buccal mucosa in the year of
20051. These patients had a high incidence of tobacco
smoking, alcohol consumption and betel nut chewing,
and may experience a relatively high rate of comor-
bidities associated with these agents compared with
persons with cancer at some other anatomic sites.
Approximately 10–20% of head and neck malig-
nancies are diagnosed in patients aged older than 
65 years1,2. In the past, these patients were not consid-
ered good candidates to receive surgery, chemotherapy
or even radiotherapy and probably were inadequately
treated without combined therapies. Currently, prog-
ress in anesthetic reanimation and improvements in
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surgical reconstruction allow an increased choice of
surgeries during the decision-making process for the
elderly.
The purpose of this study was to evaluate the sur-
vival rate of carcinoma of the oral cavity in the elderly
with different staging. To date, few publications in 
the literature have examined oral cancer in an older
population.
Materials and Methods
From 2002 to 2004, 418 new patients with SCC of the
oral cavity (including oral tongue and buccal mucosa)
were evaluated, treated and followed up at the Mackay
Memorial Hospital, Taipei, Taiwan2. We selected 65 as
the cut-off age, in line with the definition of elderly,
and analyzed the outcome after treatment in these
two groups.
Seventy patients fulfilled the criteria to be consid-
ered for the older patient group, and 348 patients
were enrolled in the younger group arm of the study.
The following data were recorded from the patient
files: age, stage, treatment modalities, and outcome.
All tumors were staged according to the American
Joint Committee on Cancer (AJCC) System, 2002. The
patterns of treatment include surgery alone, radio-
therapy alone, concurrent chemotherapy and radio-
therapy (CCRT), surgery plus chemotherapy, surgery
plus radiotherapy, and surgery plus CCRT. The outcome
was evaluated as the overall survival (OS) and disease-
free survival (DFS). Clinical staging and management
was assessed by the decision of a multidisciplinary
team.
Estimates of survival were computed with the
Kaplan-Meier product limit method. All data were
analyzed with SPSS 12.0 statistical software system
(SPSS Inc., Chicago, IL, USA). A p value of < 0.05 was
considered statistically significant.
Results
In the older group of 70 patients, 13 cases presented
as stage I, 10 as stage II, 14 as stage III, 25 as stage IVA,
six as stage IVB, and two as stage IVC (Table 1). In the
younger group of 348 patients, three cases presented
as carcinoma in situ stage, 79 as stage I, 58 as stage II,
32 as stage III, 139 as stage IVA, 28 as stage IVB, and
nine as stage IVC (Table 2). The treatment patterns in
patients of each stage were also demonstrated in
these tables.
The OS data were distributed as follows between
the older and the younger groups: 67.13% vs. 77.33%
for those with stage I, 56.00% vs. 70.31% for those with
stage II, 64.29% vs. 56.25% for those with stage III,
22.44% vs. 45.91% for those with stage IVA, and 16.67%
vs. 8.04% for those with stage IVB (Tables 3 and 4,
Figures 1 and 2).
The data of DFS were distributed as follows between
the older and the younger groups: 69.23% vs. 71.37%
for those with stage I, 45.00% vs. 65.65% for those with
stage II, 50.00% vs. 56.25% for those with stage III,
25.20% vs. 45.36% for those with stage IVA, and 16.67%
vs. 8.33% for those with stage IVB (Tables 5 and 6,
Figures 3 and 4).
There were no significant differences between the
two groups in stage I (p = 0.901 in OS, p = 0.889 in DFS),
stage II ( p = 0.345 in OS, p = 0.169 in DFS), stage III
(p = 0.348 in OS, p = 0.119 in DFS), stage IVB (p = 0.234
in OS, p = 0.236 in DFS), stage IVC ( p = 0.086 in OS).
However, the survival after treatment was better in the
younger group than the older group for stage IVA
(p = 0.009 in OS, p = 0.005 in DFS) (Table 7).
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Table 1. Treatment patterns in patients ≥ 65 years of age
Stage/Tx Surgery RT CCRT S + CT S + RT S + CCRT Total
I 9 1 1 2 13
II 4 1 1 2 2 10
III 2 3 3 4 1 1 14
IVA 4 6 4 1 3 7 25
IVB 1 3 2 6
IVC 2 2
Total 19 14 11 7 7 12 70
Tx = treatment; RT = radiotherapy; CCRT = concurrent chemotherapy and radiotherapy; S = surgery.
Discussion
Traditionally, SCC of the oral cavity is a disease target-
ing middle-aged men who habitually use tobacco,
alcohol and betel nuts. We anticipated that poor toler-
ability to treatment in older patients led to undertreat-
ment3. This point of view is correlated to our studies:
fewer combined treatments were performed for the
prevention of more comorbidities. There is a consen-
sus on treating these older patients as candidates for
conventional protocols even if there are conflicting
data in the literature on the incidence of treatment-
related deaths4. Italiano et al.5 reported that older
patients undergoing the surgical procedures of head
and neck malignancies have the same rate of postop-
erative complications as younger patients. Age by itself
may be not a reliable parameter for decision making.
Personal performance and nutritional status are
another important factor impacting the choice of
treatment. Furthermore, Arduino et al.6 revealed a 
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Table 2. Treatment patterns in patients < 65 years of age
Stage/Tx Surgery RT CCRT S + RT S + CCRT Total
0 (Tis) 3 3
I 49 3 20 7 79
II 33 4 15 4 2 58
III 5 2 7 3 15 32
IVA 8 13 36 14 68 139
IVB 10 11 7 28
IVC 3 4 2 9
Total 98 35 93 21 101 348
Tx = treatment; RT = radiotherapy; CCRT = concurrent chemotherapy and radiotherapy; S = surgery; Tis = carcinoma in situ.
Table 3. Overall survival (OS) in patients ≤ 65 years of age during 2004–2006
AJCC stage Total no. No. of deaths No. of survivals 3-year OS (%) 4-year OS (%)
0 3 0 3 100 100
I 79 15 64 80.00 77.33
II 58 14 44 75.00 70.31
III 32 14 18 56.25 56.25
IVA 139 67 72 49.74 45.91
IVB 28 24 4 16.07 8.04
IVC 9 8 1 – –
Total 348 142 206
AJCC = American Joint Committee on Cancer.
Table 4. Overall survival (OS) in patients > 65 years of age during 2004–2006
AJCC stage Total no. No. of deaths No. of survivals 4-year OS (%)
I 13 4 9 67.13
II 10 4 6 56.00
III 14 5 9 64.29
IVA 25 17 8 22.44
IVB 6 5 1 16.67
IVC 2 2 0 –
Total 70 37 33
AJCC = American Joint Committee on Cancer.
significant increase in mortality in ages over 70, and
Cinamon et al.7 reported a higher incidence of major
posttreatment complications in the senior group.
Radiotherapy is usually available in the treat-
ment of elderly population and was given either as an
alternative to surgery or as a standard treatment. Eighty-
one percent of older patients were able tolerate radio-
therapy (conventional fractionated or hypo-fractionated/
split courses) without severe toxic reactions5,8. Con-
sidering the entire patient population that received
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Figure 1. Overall survival in patients ≤ 65 years of age during
2004–2006.
Figure 2. Overall survival in patients >65 years of age during
2004–2006.
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Table 5. Disease-free survival (DFS) in patients ≤ 65 years of age during 2004–2006
AJCC stage Total no. No. of deaths No. of survivals 3-year DFS (%) 4-year DFS (%)
0 3 0 3 100 100
I 79 19 60 74.12 71.37
II 58 16 42 70.34 65.65
III 32 14 18 56.25 56.25
IVA 139 67 72 46.66 45.36
IVB 28 24 4 16.67 8.33
Total 339 140 199
AJCC = American Joint Committee on Cancer.
Table 6. Disease-free survival (DFS) in patients > 65 years of age during 2004–2006
AJCC stage Total no. No. of deaths No. of survivals 4-year DFS (%)
I 13 4 9 69.23
II 10 5 5 45.00
III 14 7 7 50.00
IVA 25 18 7 25.20
IVB 6 5 1 16.67
Total 68 39 29
AJCC = American Joint Committee on Cancer.
definitive radiotherapy, the rate of complete response
was similar in both groups9.
In this study, 16.7% (70/418) of SCCs of the oral cav-
ity were diagnosed. Most patients younger than 65 in
the early stage (stage I, 49/79; stage II, 33/58) received
surgery only, while most of those younger than 65 in
stage IVA (68/139) received surgery plus CCRT. The man-
agement of elderly patient care in each stage was not
confined in surgery only or radiotherapy alone as any
formal protocols, because the treatment was based on
multiple considerations about the condition and per-
formance of patients, choice of families, and preferences
of team doctors. Nearly one-third of the patients younger
than 65 years presented as stage IV, while elderly patients
with oral cancer did not cluster in early or late stages
when diagnosed.
The overall and disease-free survival rates for patients
in early stages were comparable to those reported previ-
ously for a younger group5. In our study, the same result
was obtained. The data of DFS were distributed between
the older and the younger groups: 69.23% vs. 71.37% for
those with stage I, and 45.00% vs. 65.65% for those with
stage II. There were no significant differences between
the two groups in stage I (p = 0.901 in OS, p = 0.889 in
DFS) or stage II (p = 0.345 in OS, p = 0.169 in DFS). The
outcome of patients with stage III/IV disease was partic-
ularly poor5. In our series, the 4-year DFS in the older and
younger groups were: 50.00% vs. 56.25% for stage III,
25.20% vs. 45.36% for stage IVA, and 16.67% vs. 8.33% for
stage IVB. There were no significant difference between
the two groups in stage III (p = 0.348 in OS, p = 0.119 
in DFS), stage IVB (p = 0.234 in OS, p = 0.236 in DFS) or
stage IVC (p=0.086 in OS). The survival was also poor in
the older groups in stage IVA (p = 0.009 in OS, p = 0.005
in DFS). The adverse outcome most likely was related
to suboptimal management as previously described.
The most important predictors of survival in the
elderly were the malignancy itself (metastases, recur-
rence) and the presence of secondary malignancies,
comorbidities or treatment-related complications. The
exact answer was not easily found, because many risk
factors may have interfered. Future research on this
point could benefit from more integrated or sensitive
measurement methods.
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Table 7. The p value of both groups
Stage
No. of patients p
> 65 years ≤ 65 years OS DFS
I 13 79 0.901 0.889
II 10 58 0.345 0.169
III 14 32 0.348 0.119
IVA 25 139 0.009 0.005
IVB 6 28 0.234 0.236
IVC 2 9 0.086 –
OS = overall survival; DFS = disease-free survival.
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Figure 3. Disease-free survival in patients ≤ 65 years of age
during 2004–2006.
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Figure 4. Disease-free survival in patients > 65 years of age
during 2004–2006.
In conclusion, SCC of the oral cavity in elderly patients
did not seem to have a significantly different outcome
when compared with younger patients. Elderly patients
with stage IVA SCC of the oral cavity had a poorer sur-
vival rate. When properly evaluated and monitored,
conservative and conventional therapy seemed effica-
cious in the elderly.
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